Showing 8701-8710 of 20878 results for "".
No improvements in CV outcomes at 90 days with human ApoA-1 infusions post-MI
https://reachmd.com/programs/acc-action-center/no-improvements-in-cv-outcomes-at-90-days-with-human-apoa-1-infusions-post-mi/24288/ACC.24 - Michael Gibson shares the results of the AEGIS-II trial, in which infusions of human ApoA-1 - the building block of HDL-c - with CSL112 in the first month after an MI did not improve CV mortality, MI or stroke at 90 days.Comparing Trial Designs & Outcomes Across IGF-1R Therapies
https://reachmd.com/programs/cme/comparing-trial-designs-outcomes-across-igf-1r-therapies/60945/Explore how experts are rethinking TED severity and integrating modern therapies to personalize treatment and manage individual disease burden.Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
https://reachmd.com/clinical-practice/cardiology/hypertrophic-cardiomyopathy-moving-from-monitoring-to-action-in-the-era-of-myosin-inhibitors/56461/Find out how myosin inhibitor data support timely identification and treatment of eligible patients with HCM.Clear Skin, Clear Path: Transforming Psoriasis Care with Durable Biologic and Oral IL-23 Innovations
https://reachmd.com/programs/cme/clear-skin-clear-path-transforming-psoriasis-care-with-durable-biologic-and-oral-il-23-innovations/49227/Join us to learn practical strategies for earlier systemic therapy initiation and why you should consider integrating oral IL-23 inhibitors into psoriasis management.Practical Dermatology Roundtable: The Role of Adjuvant Skin Cleansing and Moisturizing in Treating Psoriasis and Other Inflammatory Diseases, Ch. 7
https://reachmd.com/programs/the-practical-dermatology-roundtable/practical-dermatology-roundtable-the-role-of-adjuvant-skin-cleansing-and-moisturizing-in-treating-psoriasis-and-other-inflammatory-diseases-ch-7/56875/In the seventh installment of this eight-part series, host Ted Lain, MD, MBA, FAAD, and guests Zoe Diana Draelos, MD, and Firas George Hougeir, MD, FAAD, shift to clinical applications, including maintenance therapy, steroid-sparing strategies, and opportunities for future research.1 Draelos Z, HouFrom Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans
https://reachmd.com/programs/cme/from-evidence-to-action-integrating-emerging-myosin-inhibitors-into-ohcm-treatment-plans/54841/Explore how cardiac myosin inhibitors are reshaping obstructive HCM management, from unmet needs to individualized, evidence-based treatment.Redefining oHCM Care: Efficacy and Safety of Myosin Inhibitors
https://reachmd.com/programs/cme/redefining-ohcm-care-efficacy-and-safety-of-myosin-inhibitors/54840/Explore how cardiac myosin inhibitors are reshaping obstructive HCM management, from unmet needs to individualized, evidence-based treatment.Understanding IgAN & FSGS: Pathophysiology and Emerging Therapies
https://reachmd.com/programs/cme/understanding-igan-fsgs-pathophysiology-and-emerging-therapies/14974/Hear experts discuss how emerging therapies for IgAN and FSGS may achieve proteinuria remission and shape clinical treatment decisions for patients.In Your Waiting Room: The Virtual IBS-C Patient Clinical Experience
https://reachmd.com/programs/cme/in-your-waiting-room-the-virtual-ibs-c-patient-clinical-experience/14955/What else can you do for your patients with IBS-C whose current therapies aren’t enough? Join our experts to explore the stories of 3 patients.How to Identify & Manage Patients with Progressive-Fibrosing ILD
https://reachmd.com/programs/cme/how-to-identify-and-manage-patients-with-progressive-fibrosing-ild/10942/ILD diagnosis is complex and management can be tricky. Hear how to navigate this path and how the patient’s perspective can influence the care plan.